

Amendments to the claims:

Claims 1-25 (Cancelled).

26. (New) Paroxetine hydrochloride anhydrate in Form B; which Form comprises the following characteristics: a melting point of about 138°C.; IR bands at about 538, 574, 614, 675, 722, 762, 782, 815, 833, 884, 925, 938, 970, 986, 1006, 1039, 1069, 1094, 1114, 1142, 1182, 1230, 1274, 1304, 1488, 1510, 1574, 1604, 1631 cm⁻¹; a DSC maximum endotherm, measured at 10°C. per minute, of about 137°C. in both open and closed pans; characteristic X-ray diffractogram peaks at about 5.7, 11.3, 12.4, 14.3 degrees 2 theta; characteristic solid state ¹³C-NMR spectrum peaks at about 154.6, 148.3, 150.1, 141.7, 142.7, 139.0 ppm.

27. (New) A pharmaceutical composition comprising paroxetine hydrochloride anhydrate in Form B and a pharmaceutically acceptable carrier, which Form B comprises the following characteristics: a melting point of about 138°C.; IR bands at about 538, 574, 614, 675, 722, 762, 782, 815, 833, 884, 925, 938, 970, 986, 1006, 1039, 1069, 1094, 1114, 1142, 1182, 1230, 1274, 1304, 1488, 1510, 1574, 1604, 1631 cm⁻¹; a DSC maximum endotherm, measured at 10°C. per minute, of about 137°C. in both open and closed pans; characteristic X-ray diffractogram peaks at about 5.7, 11.3, 12.4, 14.3 degrees 2 theta; characteristic solid state ¹³C-NMR spectrum peaks at about 154.6, 148.3, 150.1, 141.7, 142.7, 139.0 ppm.

28. (New) A method for treating or preventing any one or more of the Disorders by administering an effective therapeutic or prophylactic amount of the products of the invention to a patient in need thereof.

29. (New) Paroxetine hydrochloride anhydrate in Form D; which form comprises the following characteristics: a melting point of about 125°C. and is also characterized in that it has essentially similar physical characteristics when prepared from a toluene precursor solvate using methods generally described herein said toluene precursor solvate having significant IR bands at about 1631, 1603, 1555, 1513, 1503, 1489, 1340, 1275, 1240, 1221, 1185, 1168, 1140, 1113, 1101, 1076, 1037, 1007, 986, 968, 935, 924, 885, 841, 818, 783, 760,

U.S. Serial No.: 10/217,258

Group Art Unit: Unknown

742, 720, 698, 672, 612, 572, 537 and 465 cm-1, and characteristic X-ray diffraction peaks at 7.2, 9.3, 12.7 and 14.3 degrees 2 theta.

30. (New) A pharmaceutical composition comprising paroxetine hydrochloride anhydrate in Form D and a pharmaceutically acceptable carrier, which Form D comprises the following characteristics: a melting point of about 125°C. and is also characterized in that it has essentially similar physical characteristics when prepared from a toluene precursor solvate using methods generally described herein said toluene precursor solvate having significant IR bands at about 1631, 1603, 1555, 1513, 1503, 1489, 1340, 1275, 1240, 1221, 1185, 1168, 1140, 1113, 1101, 1076, 1037, 1007, 986, 968, 935, 924, 885, 841, 818, 783, 760, 742, 720, 698, 672, 612, 572, 537 and 465 cm-1, and characteristic X-ray diffraction peaks at 7.2, 9.3, 12.7 and 14.3 degrees 2 theta.